Ceftin


Also found in: Dictionary, Medical.
Related to Ceftin: cefuroxime
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for Ceftin

a cephalosporin that can be given parenterally (trade name Zinacef) or orally by tablets (trade name Ceftin)

References in periodicals archive ?
In the fourth quarter of 2003, the Company increased its reserve for Ceftin product returns by $12.
The Company believes a presentation of the 2004 and 2003 financial results without the impact of the payments for Ceftin returns, and without the impact of the Xylos write downs, is useful in viewing the Company's underlying performance for those years.
Second-generation cephalosporin antibiotics on the approved list include Cefaclor, Cefaclor ER, Ceftin, Cefzil, Ceptaz, and Rocephin, while Ceclor CD, Cedar, Cefotan, and Lorabid must receive authorization.
She reported on 99 patients aged 18 or older in the Ceftin and Flonase for Sinusitis (CAFFS) trial, a double-blind, randomized, placebo-controlled study conducted at 12 primary care and 10 otolaryngology practice sites.
During the fourth quarter, PDI was made aware by certain wholesalers of previously undisclosed amount of Ceftin that remained in inventory.
sales of Ceftin and cefuroxime axetil tablets in 250 and 500 mg strength were approximately $239 million for the past twelve months, ending in March, 31, 2003.
In addition, according to the complaint, PDI materially misled the investing public to the true impact that the introduction of generic competition for Ceftin -- a drug which the Company was distributing under contract with GlaxoSmithKline PLC ("Glaxo") -- would have on its business.
The ruling means Apotex cannot launch a generic form of Ceftin in the U.
The decline in revenue was caused by the discontinuation of PDI's sales, marketing and distribution agreement with GlaxoSmithKline (GSK) for Ceftin in February 2002.
US sales of Ceftin declined 80%, due to generic competition which began during the first quarter.
In addition, according to the complaint, PDI materially misled the investing public as to the true impact that the introduction of generic competition for Ceftin -- a drug which the Company was distributing under contract with GlaxoSmithKline PLC ("Glaxo") -- would have on its business.
Stronger than expected Ceftin sales primarily drove these results, offset in part by no Evista revenue contribution.